Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: α- Lipoic acid Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

NCT02115724
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray
Dietary Supplement · Other · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

NCT04042935
View directory record Official record
Conditions
HNSCC
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Alpha Lipoic Acid and Insulin Resistance

NCT00845156
View directory record Official record
Conditions
Insulin Resistance
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 1, 2026, 9:26 AM EDT
Withdrawn Phase 2 Interventional

Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

NCT01471652
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Nutraceutical supplements, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional

Mitochondrial Cocktail for Gulf War Illness

NCT02804828
View directory record Official record
Conditions
Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorders
Interventions
Individualized mitochondrial cocktail, Placebo
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
48 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional

An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia

NCT01355952
View directory record Official record
Conditions
Obesity, Weight Loss, Schizophrenia
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease

NCT02774226
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tetrahydrobiopterin (BH4), Antioxidant Cocktail
Drug · Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

NCT01398423
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Active Control, INV-144
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Garden Grove, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

NCT03809611
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844-Cl, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Mission Hills, California • Newport Beach, California • Largo, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 1, 2026, 9:26 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals

NCT05083546
View directory record Official record
Conditions
Obesity, Aging
Interventions
Gly-low, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 1, 2026, 9:26 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

NCT05713799
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Alpha-lipoic acid, Mirabegron, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional

Immune Restoration by Lipoic Acid in AIDS

NCT00033176
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Effect of Mental Health Disorders on Vascular Function and Exercise Tolerance

NCT03216980
View directory record Official record
Conditions
Mental Health Disorders
Interventions
PTSD/GAD Antioxidant, PTSD/GAD Placebo, Healthy Control Antioxidant, Healthy Control Placebo
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 1, 2026, 9:26 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Vestibular Function Using Mitochondrial Antioxidant Therapy

NCT05945160
View directory record Official record
Conditions
Vestibular Function Disorder
Interventions
Alpha Lipoic Acid 300mg, Coenzyme Q10 200mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

NCT00237718
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, Alpha lipoic acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lipoic Acid and Prevention of Heart Disease

NCT00765310
View directory record Official record
Conditions
Atherosclerosis
Interventions
R-alpha lipoic acid, Placebo
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 1, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hunger Perception and Weight-Related Outcomes Following Use of a Leptin-Supporting Dietary Supplement

NCT07442864
View directory record Official record
Conditions
Hunger, Weight Change
Interventions
Leptin Balance Formula
Dietary Supplement
Lead sponsor
Efforia, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

NCT00122447
View directory record Official record
Conditions
Impaired Glucose Tolerance, Prediabetic State
Interventions
Aspirin, Alpha lipoic acid, Olmesartan, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

NCT01188811
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
lipoic acid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT02168140
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity

NCT06242535
View directory record Official record
Conditions
Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment, Physical Disability, Depression, Inflammation, Hormone Deficiency, Physical Inactivity, Hyperlipidemias, Hypertension, Overeating
Interventions
GLY-LOW
Biological
Lead sponsor
Hoskinson Health and Wellness Clinic
Industry
Eligibility
56 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gillette, Wyoming
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Understanding the Exercise-Hypertension Paradox

NCT02034422
View directory record Official record
Conditions
Hypertension
Interventions
Oral Antioxidant, Exercise rehabilitation
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 1, 2026, 9:26 AM EDT
Withdrawn Early Phase 1 Interventional

Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth

NCT03420976
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
Novel Supplement Based Therapy
Dietary Supplement
Lead sponsor
Atrium Innovations
Industry
Eligibility
19 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 1, 2026, 9:26 AM EDT